Neuroprotection: a realistic goal for aged brain?
D000109:Acetylcholine / Q000378:metabolism; D000375:Aging / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D003704:Dementia / Q000503:physiopathology / Q000517:prevention & control*; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009530:Nicergoline / Q000627:therapeutic use; D009569:Nitric Oxide / Q000235:genetics / Q000378:metabolism; D018697:Nootropic Agents / Q000627:therapeutic use; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D020127:Recovery of Function / Q000187:drug effects; D014722:Vestibule, Labyrinth / Q000187:drug effects / Q000502:physiology
D018696:Neuroprotective Agents; D018697:Nootropic Agents; D016194:Receptors, N-Methyl-D-Aspartate; D009569:Nitric Oxide; D009530:Nicergoline; D000109:Acetylcholine; D004298:Dopamine